Primary liver cancer is a very common malignant tumor with especially higher incidence in China， very tough treatment and poor prognosis， which mainly consisted of hepatocellular carcinoma （HCC）. The pathogenesis， clinical features， biological behavior， prognosis and treatment selection in Chinese patients are markedly different from those patients in western countries. It is of great significance to explore reasonable treatment strategies of Chinese population. Sorafenib is an oral， multi-targeted， multi-kinase inhibitor， which has been proved to prolong the survival of patients with advanced HCC by large scale， international clinical studies. Sorafenib has been used in China for more than 6 years and demonstrated its good efficacy and safety. However， there are many shortcomings of it. Recently， the domestic scholars have carried out many clinical studies of sorafenib monotherapy and in combination with other drugs or methods to improve its efficacy. This paper comprehensively reviews current situation and progress of related studies.

Objective  To investigate the mechanism of miR-21 regulating autophagy of non-small cell lung cancer（NSCLC） by targeting autophagy-related target gene 5 （Atg5） and its role in proliferation， migration and invasion of A549 cells. Methods  Nonsense nucleic acid sequence NC （NC group）， miR-21 mimics （miR-21 mimics group） and miR-21 inhibitor（miR-21 inhibitor group） were transfected into A549 cells， respectively. CCK-8 was used to detect the proliferation of A549 cells， scratch test was used to detect the migration ability of A549 cells， and Transwell invasion test was used to detect the invasion ability of A549 cells. Dual luciferase reporter gene assay verified the targeting relationship between miR-21 and Atg5. Western blotting was used to detect the expression of LC3B-II， p62 and Atg5 proteins. Results  Compared with NC group， the proliferation， migration and invasiveness of the cells in the miR-21 mimics group were up-regulated， while the proliferation， migration and invasiveness of the cells in the miR-21 inhibitor group were down-regulated （P＜0.05）. The results of double luciferase report experiment showed that miR-21 significantly inhibited the luciferase activity of wild-type Atg5 3’-UTR plasmid transfected cells （P＜0.05）， but had no effect on the luciferase activity after co-transfection of mutant Atg5 3’-UTR gene report plasmid with miR-21 mimics. The expression of LC3B-II protein in NC group was lower than that in miR-21 mimics group， higher than that in miR-21 inhibitor group （P＜0.05）； the expression of p62 and Atg5 protein in NC group was higher than that in miR-21 mimics group， lower than that in miR-21 inhibitor group  （P＜0.05）. Compared with NC group， 3-MA treatment decreased the proliferation of A549 cells induced by miR-21 mimics transfection （P＜0.05）. Scratch and Transwell experiments showed that 3-MA treatment inhibited the migration and invasion of A549 cells induced by miR-21 mimics transfection （P＜0.05）. Conclusion MiR-21 targeting Atg5 regulates autophagy in non-small cell lung cancer cells and promotes proliferation， migration and invasion of lung cancer cells.

Tumor-draining lymph node，abbreviated as TDLN， refers to the lymph node affected by tumor cells through lymphatic ducts， including various types of immune cells， like nature killer cells， T cells， antigen presenting cells and B cells. Because of the presence of these immune cells and the unique location of TDLN located downstream of the tumor， TDLN becomes an important site of anti-tumor immune response. However， TDLN， often developing immune tolerance to the tumor， becomes the transfer relay station of tumor cells to other tissues. In the immunotherapy of TDLN， except vitro-activate cell therapy and in vivo-activated cell therapy， some new treatments， such as targeted therapy， are becoming the focus of research. This article reviews the immunological properties of TDLN， and the mechanism and research progress of TDLN related immunotherapy.

Objective To investigate the status and trends of prostate cancer incidence in China. Methods The registered prostate cancer data between 1998 and 2008 from the National Cancer Registration Center was collected， including the incidence of prostate cancer， the cumulative probability of developing prostate cancer of males aged 0.74， composition and agespecific incidence. The status and trends of the incidence between urban and rural men was compared and analyzed. Results In 2008， the incidence of prostate cancer of Chinese men was 11.00／100 000， accounting for 3.33％ of the incidence of mens malignant tumors. The worlds population agestandardized incidence rate was 6.73／100 000. The cumulative risk of males aged 0.74 was 0.70％. The incidence of urban males was about 3.7 times of that in rural areas. The results of agespecific incidence showed that the incidence of Chinese males over the age of 70 ranked the first place in the males genitourinary tumor. The average annual growth rate during 19982008 was 12.07％. The growth incidence rate of urban men with prostate cancer was 8.53/100 000, higher than 2.53/100 000 in rural areas. But the average annual growth rate of urban males was 11.25%, lower than 13.28% of rural males. The proportion of high age group was increased significantly in the age composition of the incidence over time. Conclusion In recent years， the incidence of prostate cancer have showed an obvious growth trend in China. Prostate cancer is becoming urinary tract malignant tumor that impacts Chinese mens health seriously.

Lung cancer remains as a greatest threat to human health. Traditional Chinese medicine（TCM） has unique theoretical system in the treatment of lung cancer and has shown definite efficacy. Integration of traditional Chinese and western medicine is the mainstream and trend for lung cancer treatment. Although achievements have been made in the field of clinical and basic research，there still lacks of methodology and technology which could reflect the real diagnosis and treatment regularity of lung cancer. With further development，lung cancer treatment with TCM will improve in the future.

Targeted therapies by means of compounds that inhibit a specific target molecule represent a new perspective in the treatment of cancer. Various signaling pathways have been implicated in the development and progression of cancer. There is a general agreement that molecules interfering simultaneously with multiple targets might be more effective than single target agents. Regorafenib （BAY 73-4506） is a novel， oral multikinase inhibitor， which demonstrates a broad spectrum of antitumor activity， probably due to the targeting of several angiogenic， oncogenic and stromal kinases. On September 2012， regorafenib was approved by US Food and Drug Administration（FDA） for previously heavy treated metastatic colorectal cancer. On February 2013， US FDA expanded the approved use to treat patients with advanced gastrointestinal stromal tumors. Two large， randomized，international multicentre，phase Ⅲ clinical trial in patients with metastatic colorectal cancer and gastrointestinal stromal tumour treated by regorafenib were finished. The CORRECT trial evaluated regorafenib for the treatment of patients with metastatic colorectal cancer who had progressed after standard therapies. The results confirmed that regorafenib was associated with significant improvements in overall survival. The GRID trial showed that regorafenib could provide a significant improvement in progressionfree survival compared with placebo in patients with metastatic gastrointestinal stromal tumour following failure of imatinib and sunitinib. The toxicity profile of regorafenib is comparable with other oral multikinase inhibitors with similar molecular targets. Most toxicities associated with regorafenib are mild／moderate and clinically managable. Further extensive clinical development as a single agent or in combination with standard chemotherapeutic agents in various malignant tumors is ongoing.

It is generally accepted that the occurrence and development of cancer are closely related to tumor angiogenesis. Vascular endothelial growth factor and its receptor（VEGF/VEGFR）signal pathway plays an important role in regulating and controlling angiogenesis，and is also the key target of many kinds of anti-angiogenesis drugs. Mesylate apatinib is a new and small molecular anti-angiogenesis drug，which can strongly against tumor angiogenesis by inhibiting VEGFR-2 with highly selectivity. A series of clinical trials confirms that there were certain objective response and obvious survival benefit to advanced gastric cancer patients treated by apatinib, who failed in the standard chemotherapy，also with better safety. Currently， trials and clinical studies of apatinib alone or in combination with other drugs for lung cancer, hepatic cancer, gastric cancer, colorectal cancer and breast cancer are carried on. This article reviewed fundamental experiments and clinical trials to provide reference for further using of apatinib in clinic.

Antineoplastic drug-induced liver injury（DILI），one of the most common clinical problems，has been increasingly concerned. As multifunctional hepatoprotective drugs of anti-inflammatory class，glycyrrhizin，especially the latest glycyrrhizin magnesium isoglycyrrhizinate，has been used for the prevention and treatment of DILI recently. This paper reviewed the current situation and research progress of magnesium isoglycyrrhizinate in the prevention and treatment of DILI in the hematological malignancy，solid tumor，hepatic artery embolism chemotherapy and molecular target therapy，and discussed the future direction of development.

Metaplastic breast carcinoma（MBC） is a rare and heterogeneous subtype of breast carcinoma with generally poor prognosis. MBC usually present with larger tumor， less nodal involvement， higher histological grade， and lack hormone and HER2 receptor expression. This review will describe the characteristics of clinical，histopathological，immunohistochemical，genetic， diagnostic， therapeutic and prognostic in this generally poor prognosis malignancy.